Active ingredient : Enzalutamide
Strength : 40MG
Package : 28 capsules
Category : Anti-neoplastic agent
Xtandi is a hormonal therapy used for advanced prostate cancer treatment, like for 0men who are all affected with prostate carcinoma in metastatic stage. These are majorly indicated for prostate carcinoma, which contains Enzalutamide, as an active component considered as non steroidal anti-androgen medication. It is involved in association with castration in the therapy of metastatic or long lasting castration resistant prostate cancer. It is a prescribing medicine, the main ingredient which is used as enzalutamide,only prescribed by medical oncologist.
XTANDI DOSING CONDITIONS AND ADMINISTRATION
The usual prescribed dosage of Xtandi is 160mg as a single dose by taking with or without food. Xtandi is available in the strength of 40mg; four Capsules of Xtandi should be administered at a same time. Xtandi Capsule should not crush, not chew taken with glass of water. Xtandi Dosing adjustment: In patients with ≥ grade III toxicity: Xtandi 40mg therapy should be refuse for one week or the symptoms should be reduced to grade II, then restart with same dose or decreased to 80mg or 120mg Strong CYP2C8 inhibitors: While combining with Xtandi Capsule, the dosage should be modified by reducing to 80mg as a single dose or avoid this combination. Strong CYP3A4 inducers: Co administration of Xtandi with Strong CYP3A4 inducers, xtandi dosage increased up to 240mg or stop this combination.
An androgen which is a male hormone is used to develop prostate carcinoma. One of the major hormone secreted by testes and adrenal glands is known as testosterone. Xtandi containing Enzalutamide will interfere with testosterone production, causes tumor cell growth depletion. It interfere with androgen receptor signaling transduction and leads to cancer cell lysis
After receiving 160mg of Xtandi for mCRPC, from median time to attain peak plasma concentration time at 1 hour (variation with 0.5 to 3 hours). The steady state level of Xtandi is accomplished by day 28 Food does not cause any alteration in absorption of Xtandi Capsules.
Volume of distribution 110L High plasma protein bounding capacity of Xtandi Capsules is occurs as 97% to 98%
Two most prominent cytochrome isoenzymes are involved in metabolism of Xtandi Capsules; There are two isoenzymes i.e CYP2C8 & CYP3A4; in which CYP2C8 is vital for production of N-desmethyl Enzalutamide which is an active metabolite of Enzalutamide.
Xtandi Capsules undergoes excretion by hepatic metabolism Major route of elimination; 71% in urine; 14% in feces The terminal half life period of Xtandi Capsules is 5.8 days (range at 2.8 to 10.2 days); N-desmethyl Enzalutamide has half life period of relatively 7.8 to 8.6 days.
WARNING AND PRECAUTIONS
During the treatment with Xtandi Capsules, patient may suffer with some adverse effects like; Posterior reversible encephalopathy syndrome Seizures In PRES, some neurological disorders occur in patients. The condition can recovered by providing safety measures or discontinue the therapy as soon as possible. PRES is recognized by using MRI In seizures, Before starting the treatment patient must counsel about this adverse reaction and Stop the therapy if possible. Spermatogenesis occurs that may prohibit the male fertility leads to hypo spermatogenesis. In androgen decline the treatment, may have increase exposure of cardiovascular disease like worsening hypertension.
Pregnancy category of Xtandi Capsule is D Xtandi is contraindicated to pregnancy; it may cause fetal harm even to death.
Breast feeding is not suggested, Xtandi is contraindicated in lactation
Xtandi 40mg is a chem. Drug, used in prostate cancer. Xtandi Capsule should not be self medicated, used by the patients only after getting advice from the medical oncologist. If a single dose missed by patient, then must consult with the physician and follow the instructions as per the guidance of medical adviser, the missed dose should be taken within a time or avoid the missed dose and follow the regular schedule.
Xtandi 40MG INTERACT WITH SOME DRUGS LIKE
Xtandi drug combined with CYP2C8 strong inhibitors, causes elevation of plasma concentration time curve of Enzalutamide and its active metabolite. So avoid this combination, otherwise dosage of Xtandi should be reduced to 80mg. Xtandi with CYP2C8 strong inducers causes variation in plasma exposure of Xtandi, to minimize this problem to avoid this concomitant. Co administration of Xtandi Capsules with strong inhibitors or CYP3A4, leads to elevate the AUC of Enzalutamide and its metabolite. CYP3A4 strong inducers example like; phenytoin, Phenobarbital, carbamazepine etc combines with Xtandi Capsules causes depletes the plasma exposure of Xtandi. Moderate CYP3A4 inducers like Bosentan, efavirenz, modafinil, st Johns wort causes decreasing the plasma concentration of Xtandi Capsule. Xtandi Capsules are strong CYP3A4 inducers and moderate CYP2C8 & CYP2C19. CYP3A4 strong inducers like Midazolam, CYP2C8 inducers like warfarin, & CYP2C19 inducers like Omeprazole with Xtandi causes reducing the plasma risk of Midazolam, warfarin & Omeprazole.
Xtandi Capsules are contraindicated to pregnancy condition, which may cause fetal harm leads to death. An Anaphylactic reaction happens, if patients are contraindicated to the ingredient present in Xtandi Capsules.
In the case of over dosage of Xtandi Capsules, causes severe seizures. If occurring of over dosage , immediately discontinue the treatment and maintain the safety measures. In dose acceleration study at ≤ 240mg daily the condition seizure does not occur. If the dose of 360mg, 480mg & 600mg at high risk will causes Seizures
XTANDI SIDE EFFECTS
Some side effects during the therapy using with Xtandi; Back pain, Arthralgia, Muscular weakness, pain, Diarrhea, Hypertension & hot flush, Dizziness, headache, Asthenia conditions, Peripheral edema, Spinal cord compression, paresthesia, Mental impairment, Hypesthesia, Respiratory tract infections, Hematuria, Pollakiuria, Dry skin, Pruritus, Neutropenia, Thrombocytopenia, Increasing bilirubin level, Epistaxis, Infections like sepsis, Fractures, joint injury, and hematomas (Fall associated injuries). Hallucinations.